GSTM1 and Schnyder corneal dystrophy: An updated analysis of the results of this trial encompassing 46 SCD patients with a more extended follow-up showed that elimination of vascular occlusive events was observed in 90% of patients receiving Exa-Cel, with a marked increase in total Hb (>12 g/dL) and HbF (>40%) [87].